Inventories

6 Months Ended

Jun. 30, 2017

Inventory Disclosure [Abstract]

Inventories

Note 3: Inventories

As of June 30, 2017, the inventories of the Company, which consisted primarily of inventories of the Company's wholly owned subsidiary USC and raw materials of approximately $59,000, Active Pharmaceutical Ingredient ("API"), for our recently FDA approved product, Symjepi. Inventories consisted of the following: 

Finished Goods	$	319,446
Raw Material		474,514
Devices		156,035
	$	949,995

Reserve for obsolescence as of June 30, 2017, was $57,059.